Gainers

• ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-market session. The market value of their outstanding shares is at $6.2 million.
• Apimeds Pharmaceuticals (AMEX:APUS) shares rose 10.06% to $0.7. The company's market cap stands at $9.7 million.
• China Pharma Holding (AMEX:CPHI) stock increased by 9.62% to $8.88. The company's market cap stands at $36.8 million.
• Adagio Medical Holdings (NASDAQ:ADGM) stock increased by 9.23% to $0.48. The market value of their outstanding shares is at $11.3 million.
• Lexaria Bioscience (NASDAQ:LEXX) shares increased by 8.34% to $0.6. The market value of their outstanding shares is at $14.8 million.
• Nexalin Technology (NASDAQ:NXL) shares moved upwards by 5.92% to $0.51. The market value of their outstanding shares is at $10.8 million.

Losers

• Catheter Precision (AMEX:VTAK) shares fell 21.0% to $0.39 during Tuesday's after-market session. The market value of their outstanding shares is at $1.8 million.
• Zhengye Biotechnology (NASDAQ:ZYBT) stock declined by 11.93% to $2.51. The company's market cap stands at $379.6 million.
• Dyne Therapeutics (NASDAQ:DYN) stock declined by 11.83% to $21.0. The company's market cap stands at $3.8 billion.
• Pomdoctor (NASDAQ:POM) stock declined by 11.21% to $0.8. The company's market cap stands at $102.5 million.
• Niki BioSolutions (NASDAQ:NIKI) stock fell 9.31% to $8.67. The company's market cap stands at $71.9 million.
• First Tracks (NASDAQ:TRAX) stock decreased by 8.51% to $34.19. The company's market cap stands at $1.2 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.